Pharma

Your Article Summary

See Latest Articles

Antineoplastic Agent / Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Tarceva Application for Approval of Additional Indication of Pancreatic Cancer
Chugai Pharmaceutical Co., 09/22/09

Chugai Pharmaceutical Co., Ltd. announced that the company filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of pancreatic cancer for the antineoplastic agent / epidermal growth factor receptor tyrosine kinase inhibitor, "TARCEVA Tablet 25 mg and 100 mg" [generic name: erlotinib hydrochloride] (hereafter, Tarceva).

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals